Advances in the Treatment of Ischemic Stroke

260 Pages·2012·14.294 MB·English

by  M. Balestrino

ADVANCES IN THE
TREATMENT OF
ISCHEMIC STROKE

Edited by Maurizio Balestrino
Advances in the Treatment of Ischemic Stroke
Edited by Maurizio Balestrino

Published by InTech
Janeza Trdine 9, 51000 Rijeka, Croatia

Copyright © 2012 InTech
All chapters are Open Access distributed under the Creative Commons Attribution 3.0
license, which allows users to download, copy and build upon published articles even for
commercial purposes, as long as the author and publisher are properly credited, which
ensures maximum dissemination and a wider impact of our publications. After this work
has been published by InTech, authors have the right to republish it, in whole or part, in
any publication of which they are the author, and to make other personal use of the
work. Any republication, referencing or personal use of the work must explicitly identify
the original source.

As for readers, this license allows users to download, copy and build upon published
chapters even for commercial purposes, as long as the author and publisher are properly
credited, which ensures maximum dissemination and a wider impact of our publications.

Notice
Statements and opinions expressed in the chapters are these of the individual contributors
and not necessarily those of the editors or publisher. No responsibility is accepted for the
accuracy of information contained in the published chapters. The publisher assumes no
responsibility for any damage or injury to persons or property arising out of the use of any
materials, instructions, methods or ideas contained in the book.

Publishing Process Manager Maja Bozicevic
Technical Editor Teodora Smiljanic
Cover Designer InTech Design Team

First published February, 2012
Printed in Croatia

A free online edition of this book is available at www.intechopen.com
Additional hard copies can be obtained from [email protected]

Advances in the Treatment of Ischemic Stroke, Edited by Maurizio Balestrino
p. cm.
ISBN 978-953-51-0136-9

Contents

Preface IX
Part 1 Hypothermia in the Acute Phase 1
Chapter 1 Cerebral Ischemia and Post-Ischemic
Treatment with Hypothermia 3
Kym Campbell, Neville W. Knuckey and Bruno P. Meloni
Chapter 2 Hypothermia as an Alternative for the
Management of Cerebral Ischemia 15
Felipe Eduardo Nares-López, Gabriela Leticia González-Rivera
and María Elena Chánez-Cárdenas
Chapter 3 Timing of Hypothermia (During or After Global
Cerebral Ischemia) Differentially Affects Acute
Brain Edema and Delayed Neuronal Death 37
Masaru Doshi and Yutaka Hirashima
Chapter 4 Molecular Mechanisms
Underlying the Neuroprotective Effect
of Hypothermia in Cerebral Ischemia 43
Yasushi Shintani and Yasuko Terao
Part 2 Brain Regeneration After Stroke:
Spontaneous Events and Stem Cells Therapy 67
Chapter 5 Cortical Neurogensis in Adult Brains
After Focal Cerebral Ischemia 69
Weigang Gu and Per Wester
Chapter 6 Brain Plasticity Following Ischemia:
Effect of Estrogen and Other Cerebroprotective Drugs 89
Edina A. Wappler, Klára Felszeghy, Mukesh Varshney,
Raj D. Mehra, Csaba Nyakas and Zoltán Nagy
VI Contents

Chapter 7 The Promise of Hematopoietic
Stem Cell Therapy for Stroke:
Are We There Yet? 115
Aqeela Afzal and J. Mocco
Chapter 8 Toward a More Effective
Intravascular Cell Therapy in Stroke 141
Bhimashankar Mitkari, Erja Kerkelä, Johanna Nystedt,
Matti Korhonen, Tuulia Huhtala and Jukka Jolkkonen
Part 3 Intravenous Thrombolysis and Intra-Arterial Procedures 161
Chapter 9 Thrombolysis for Ischemic Stroke
in Patients Aged 90 Years or Older 163
M. Balestrino, L. Dinia, M. Del Sette, B. Albano and C. Gandolfo
Chapter 10 Mechanical Embolectomy 169
Jiří Lacman and František Charvát
Chapter 11 Decreased Cerebral Perfusion
in Carotid Artery Stenosis, Carotid Angioplasty
and Its Effects on Cerebral Circulation 183
Antenor Tavares and José Guilherme Caldas
Part 4 Treatment of Intracranial Hypertension 213
Chapter 12 Medical and Surgical Management
of Intracranial Hypertension 215
James Scozzafava, Muhammad Shazam Hussain and Seby John
Chapter 13 An Innovative Technique of Decompressive
Craniectomy for Acute Ischemic Stroke 227
Marcelo M. Valença, Carolina Martins,
Joacil Carlos da Silva, Caio Max Félix Mendonça,
Patrícia B Ambrosi and Luciana P. A. Andrade-Valença

Preface

The last decade or so has witnessed unprecedented advances in the therapy of
ischemic stroke. Intensive preclinical and clinical research in what used to be an
almost incurable disease is finally putting at the clinicians’ disposal powerful
therapeutic tools. While intravenous thrombolysis with recombinant tissue
plasminogen activator has been the first and is still the most used tool, other ways of
interventions have entered the clinical arena, dramatically improving the therapy of
ischemic stroke. As it always happens at times of rapid changes, clinical practice lags
behind research findings. While at times it must be so, since clinical practice must wait
for evidence confirmation, very often the clinician finds it difficult to receive and
process the relevant information in what may appear an overflow of data.
While an all-inclusive review of all available innovations in stroke therapy would
probably be impossible in a single book, this one does provide reviews and updated
information in several hot issues.
Hypothermia is the first such issue. This powerful therapy is finally coming of age, so
far the sole survivor of a host of “neuroprotective” therapies that animal research had
developed. While all other neuroprotective therapies have failed in the clinics,
hypothermia has grown to become now, basically, recommended practice in the rescue
therapy after cardiac arrest, a condition very similar albeit not identical to ischemic
stroke. Its application in stroke is currently not routine practice, because of technical
difficulties, of still significant side effects (let’s not forget that cardiac arrest often
occurs in young people, ischemic stroke in elder persons) and because of limited
clinical trials. However, there is probably sufficient evidence for considering it on a
case-by-case basis in hospitals that have experience in its application. In this book, the
contribution by Campbell et al. provide a fine review of both preclinical and clinical
issues of hypothermia. Both Nares-López et al. and Shintani and Terao convincingly
review the very extensive mechanisms of protection by hypothermia, while Doshi and
Hirashima report results from animal research concerning duration and timing of
hypothermia, results that are relevant to clinical applications of this technique.
Second, brain regeneration is considered. The last decade of the 20th century has
finally rejected the old myth that neurons remain unchanged in number from birth to
death and, if damaged, cannot be replaced. On the contrary, we now know that a
X Preface

lively neuronal regeneration is routinely under way in the brain (for example, new
neurons are continuously generated in the hippocampal dentate gyrus, a fact that is
probably important for memory). Endogenous regeneration is certainly a repair
mechanism that occurs after stroke, although still a poorly understood one. In this
book, two chapters (by Gu and Wester and by Wappler et al.) provide novel
interesting knowledge on the relevance and on the mechanisms of endogenous
regeneration after experimental animal ischemic stroke. Moreover, stem cells
administration has been extensively investigated, in the hope to replace the neurons
that had died after stroke. Unfortunately, human clinical trials in this field have been
surprisingly scarce, a fact that still leaves largely unanswered basic questions like: is
stem cells administration really useful for stroke, does it really work by replacing dead
neurons, or does it rather favor endogenous regeneration and healing, what types of
stem cells are better, what stroke types benefit the most from this therapy. Answer to
these questions is of paramount importance also because several private hospitals are
now offering expensive stem cells transplantation, a legitimate business that however
underlines an urgent need to answer the above questions. In this book the two
chapters by Afzal and Mocco and by Mitkari et al. help the interested professional
navigate this difficult field.
Clot-removal therapies for ischemic stroke (both intravenous thrombolysis and
endovascular techniques) entered the neurological armamentarium at the very end of
the last century, changing forever the way stroke is treated. As we all recall, they were
met with a mix of enthusiasm for their effectiveness and fear for their side effects,
chiefly haemorrage. Fear of haemorrhage caused a long list of exclusion criteria that, at
least in Europe, prevented intravenous thrombolysis from being administered to
many, probably most, patients. In the following years several such criteria were
challenged or revised, for example the maximum acceptable time from onset is
currently no longer considered 3 hours (as it is still stated in the official approval
documents of the therapy) but rather 4.5 hours, following the successful ECASS-III
study, and most centers are now administering intravenous thrombolysis off-label
between 3 and 4.5 hours from symptoms onset. At the time of this writing (January
2012) we are waiting for the results of the IST-3 trial, that will hopefully clarify other
issues in the administration of intravenous thrombolysis (for example, time up to 6
hours from onset, simptoms very mild or too severe, onset with epileptic seizures, and
so on). A major issue is patients’ age, in fact in Europe r-TPA for intravenous
thrombolysis is still officially approved for treatment only in patients younger than 80
y.o. However, this boundary is being strongly challenged, and in this book we
(Balestrino et al.) are reporting our so far successful experience with intravenous
thrombolysis in patients even older than 90 years.
Endovascular therapy has recently raised great interest both in the therapy of acute
stroke and in the therapy of symptomatic or asymptomatic carotid artery stenosis. As
for acute stroke, the only randomized, controlled, multicenter, open-label clinical trial
with blinded follow-up that has been so far completed is the PROACT-II, that